Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761] (Pharmacological Research (2020) 156, (S104366182030743X), (10.1016/j.phrs.2020.104761));Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Pharmacological Research

Volumn 156, Issue , 2020, Pages

  Runfeng, Li ^a   Yunlong, Hou ^e   Jicheng, Huang ^d   Weiqi, Pan ^a   Qinhai, Ma ^a   Yongxia, Shi ^d   Chufang, Li ^a   Jin, Zhao ^a   Zhenhua, Jia ^e   Haiming, Jiang ^a   Kui, Zheng ^d   Shuxiang, Huang ^d   Jun, Dai ^d   Xiaobo, Li ^d   Xiaotao, Hou ^c   Lin, Wang ^c   Nanshan, Zhong ^a   Zifeng, Yang ^a,b,c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^c KingMed Virology Diagnosis and Translational Center   (China)

^d China Southern Power Grid   (China)

^e HEBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Anti inflammatory; Coronavirus; Lianhuaqingwen; SARS CoV 2

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; LIANHUAQINGWEN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; REMDESIVIR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUH-7 CELL LINE; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SARS-RELATED CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TRANSMISSION ELECTRON MICROSCOPY; VERO C1008 CELL LINE; VIRION; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; BETACORONAVIRUS; CELL LINE; CHLOROCEBUS AETHIOPS; SCANNING ELECTROCHEMICAL MICROSCOPY; ULTRASTRUCTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; BETACORONAVIRUS; CELL LINE; CHLOROCEBUS AETHIOPS; DRUGS, CHINESE HERBAL; MICROSCOPY, ELECTROCHEMICAL, SCANNING;

EID: 85083017858     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2021.105907     Document Type: Erratum

References (20)

1. Ding, Y., et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement. Altern. Med., 17(1), 2017, 130.
2. Fung, T.S., Liu, D.X., Human coronavirus: host-pathogen interaction. Annu. Rev. Microbiol. 73 (2019), 529–557.
3. Du Toit, A., Outbreak of a novel coronavirus. Nat. Rev. Microbiol., 18(3), 2020, 123.
4. Carlos, W.G., et al. Novel Wuhan (2019-nCoV) coronavirus. Am. J. Respir. Crit. Care Med. 201:4 (2020), P7–P8.
5. Nkengasong, J., China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response. Nat. Med. 26:3 (2020), 310–311.
6. Zhou, P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:7798 (2020), 270–273.
7. Huang, C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:10223 (2020), 497–506.
8. Wang, D., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:11 (2020), 1061–1069.
9. Wu, P., et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill., 25(3), 2020.
10. Zumla, A., et al. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15:5 (2016), 327–347.
11. Mulangu, S., et al. A randomized, controlled trial of ebola virus disease therapeutics. N. Engl. J. Med. 381:24 (2019), 2293–2303.
12. Ren, J.-l., Zhang, A.-H., Wang, X.-J., Traditional Chinese medicine for COVID-19 treatment. Pharmacol. Res., 2020, 104743.
13. Yao, K., et al. Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional chinese medicine Lianhua Qingwen. Chin. J. Exp. Trad. Med. Formulae, 2020, 1–7.
14. Lu, H., Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends 14:1 (2020), 69–71.
15. Duan, Z.P., et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin. Med. J. (Engl.) 124:18 (2011), 2925–2933.
16. Li, Z., et al. Radix isatidis polysaccharides inhibit influenza a virus and influenza a virus-induced inflammation via suppression of host TLR3 signaling in vitro. Molecules, 22(1), 2017.
17. Wang, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30:3 (2020), 269–271.
18. Leong, H.N., et al. Clinical and laboratory findings of SARS in Singapore. Ann. Acad. Med. Singapore 35:5 (2006), 332–339.
19. Assiri, A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect. Dis. 13:9 (2013), 752–761.
20. Wan, S., et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv, 2020, 10.1101/2020.02.10.20021832.